Lopinavir/ritonavir: Appraisal of its use in HIV therapy

Drugs of Today

Volumn 43, Issue 4, 2007, Pages 221-247

  Von Hentig, Nils ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; AMPRENAVIR PHOSPHATE; ASTEMIZOLE; BEPRIDIL; CARBAMAZEPINE; CISAPRIDE; DIHYDROERGOTAMINE; EFAVIRENZ; ERGOMETRINE; ERGOTAMINE; FLECAINIDE; INDINAVIR; LIDOCAINE; LOPINAVIR PLUS RITONAVIR; METHYLERGOMETRINE; MEVINOLIN; MIDAZOLAM; NELFINAVIR; NEVIRAPINE; PHENOBARBITAL; PHENYTOIN; PIMOZIDE; PROPAFENONE; QUINIDINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; SIMVASTATIN; TERFENADINE; TRIAZOLAM; UNINDEXED DRUG; LOPINAVIR; PROTEINASE INHIBITOR; PYRIMIDINONE DERIVATIVE; RITONAVIR;

ABDOMINAL PAIN; ACQUIRED IMMUNE DEFICIENCY SYNDROME; AREA UNDER THE CURVE; ASTHENIA; CARCINOGENICITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FEVER; DRUG INTOXICATION; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG WITHDRAWAL; DRY SKIN; DYSLIPIDEMIA; DYSPEPSIA; ERGOT TOXICITY; FERTILITY; FOOD; FOOD DRUG INTERACTION; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART ARRHYTHMIA; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HEPATOMEGALY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERAMYLASEMIA; INSULIN RESISTANCE; LIPODYSTROPHY; MONOTHERAPY; NAUSEA; NONHUMAN; PANCREATITIS; PREGNANT WOMAN; RESPIRATION DEPRESSION; REVIEW; RHABDOMYOLYSIS; SEDATION; SEX DIFFERENCE; SIDE EFFECT; TERATOGENICITY; VIRUS INFECTION; VIRUS MUTATION; VIRUS RESISTANCE; VOMITING; ANIMAL; ANTIBIOTIC RESISTANCE; DRUG COMBINATION; DRUG EFFECT; DRUG INTERACTION; DRUG SCREENING; HUMAN IMMUNODEFICIENCY VIRUS 1;

ANIMALS; DRUG COMBINATIONS; DRUG EVALUATION, PRECLINICAL; DRUG INTERACTIONS; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; PYRIMIDINONES; RITONAVIR;

EID: 34447318665     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2007.43.4.1050793     Document Type: Review

References (127)

1. Lee, L.M., Karon, J.M., Selik, R., Neal, J.J., Fleming, P.L. Survival after AIDS diagnosis in adolescents and adults during the treatment era, United States, 1984-1997. JAMA 1998, 285: 1308-15.
2. Mocroft, A., Ledergerber, B., Katlama, C. et al.; EuroSIDA Study Group. Decline in the AIDS and death rates in the EuroSIDA study: An observational study. Lancet 2003, 362: 22-9.
3. Morgello, S., Mahboob, R., Yakoushina, T., Khan, S., Hague, K. Autopsy findings in a human immunodeficiency virus-infected population over 2 decades: Influences of gender, ethnicity, risk factors, and time. Arch Pathol Lab Med 2002, 126: 182-90.
4. Friis-Moller, N., Sabin, C.A., Weber, R. et al.; Data Collection on Adverse Events of AntiHIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003, 349: 1993-2003.
5. Roberts, N.A., Martin, J.A., Kinchington, D. et al. Rational design of peptide-based HIV proteinase inhibitors. Science 1990, 248: 358-61.
6. Sham, H.L., Kempf, D., Molla, A. et al. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob Agents Chemother 1998, 42: 3218-24.
7. Kaletra® European summary of product characteristics. Abbot Laboratories, Maidenhead 2001.
8. Kempf, D.J., Marsh, K.C., Denissen, J.F. et al. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc Natl Acad Sci USA 1995, 92: 2484-8.
9. Johnson, V., Brun-Vezinet, F, Clotet, B. et al. Update of the drug resistance mutations in HIV-1: 2005. Topics HIV Med 2005, 13: 125-31.
10. Masquelier, B., Breilh, D., Neau, D. et al.; Groupe d'Epidemiologie Clinique du SIDA en, Aquitaine. Human immunodeficiency virus type 1 genotypic and pharmacokinetic determinants of the virological response to lopinavir-ritonavir-containing therapy in protease inhibitor-experienced patients. Antimicrob Agents Chemother 2002, 46: 2926-32.
11. Kempf, D.J., Isaacson, J.D., King, M.S. et al. Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients. J Virol 2001, 75: 7462-9.
12. Loutfy, M.R., Raboud, J.M., Walmsley, S.L. et al. Predictive value of HIV-1 protease genotype and virtual phenotype on the virological response to lopinavir/ritonavir-contain-ing salvage regimens. Antivir Ther 2004, 9: 595-602.
13. Gonzalez de Requena, D., Gallego, O., Valer, L., Jimenez-Nacher, I., Soriano, V. Prediction of virological response to lopinavir/ritonavir using the genotypic inhibitory quotient. AIDS Res Hum Retroviruses 2004, 20: 275-8.
14. Gonzalez de Requena, D., Gallego, O., Blanco, F. et al. Lopinavir drug levels predict the virological and immunological outcome as well as lipid elevations. 10th Conference on Retroviruses and Opportunistic infections. Boston 2003, Abst. 525.
15. Mo, H., King, M., King, K., Molla, A., Brun, S., Kempf, D.J. Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: Mutation patterns and baseline correlates. J Virol 2005, 79: 3329-38.
16. Kempf, D.J., Isaacson, M.S., King, S.C. et al. Analysis of the virologic response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-1-infected patients receiving lopinavir/ritonavir therapy. Antivir Ther 2002, 7: 165-74.
17. de Mendoza, C., Valer, L., Bacheler, L., Pattery, T., Corral, A., Soriano, V. Prevalence of the HIV-1 protease mutation 147A in clinical practice and association with lopinavir resistance. AIDS 2006, 20: 1071-4.
18. Hoefnagel, J.G., van der Lee, M., Koopmans, P.P. et al. The genotypic inhibitory quotient and the (cumulative) number of mutations predict the response to lopinavir therapy. AIDS 2006, 20: 1069-71.
19. Mo, H., Parkin, N., Stewart, K. et al. Identification and structural characterization of I84C and I84A mutations that are associated with high-level resistance to human immunodeficiency virus protease inhibitors and impair viral replication. Antimicrob Agents Chemother 2007, 51: 732-5.
20. Parkin, NT., Chappey, C., Petropoulos, C.J. Improving lopinavir genotype algorithm through phenotype correlations: Novel mutation patterns and amprenavir cross-resistance. AIDS 2003, 17: 955-61.
21. Friend, J., Parkin, N., Liegler, T., Martin, J.N., Deeks, S.G. Isolated lopinavir resistance after virological rebound of a ritonavir/lopinavir-based regimen. AIDS 2004, 18: 1965-6.
22. Hales, G., Birch, C., Crowe, S. et al. A randomised trial comparing genotypic and virtual phenotypic interpretation of HIV drug resistance: The CREST study. PLoS Clin Trials 2006, 1: e18 (Epub ahead of print).
23. Gianotti, N., Mondino, V., Rossi, M. et al. Comparison of a rule-based algorithm with a phenotype-based algorithm for the interpretation of HIV genotypes in guiding salvage regimens in HIV-infected patients by a randomized clinical trial: The mutations and salvage study. Clin Infect Dis 2006, 42: 1470-80.
24. Breilh, D., Pellegrin, I., Rouzes, A. et al. Virological, intracellular and plasma pharmacological parameters predicting response to lopinavir/ritonavir (KALEPHAR study). AIDS 2004, 18: 1305-10.
25. Hoefnagel, J.G., Koopmans, P.P., Burger, D.M., Schuurman, R., Galama, J.M. Role of the inhibitory quotient in HIV therapy. Antivir Ther 2005, 10: 879-92.
26. Torti, C., Uccelli, M., Quiros-Roldan, E. et al. Prediction of early and confirmed virological response by genotypic inhibitory quotients for lopinavir in patients naive for lopinavir with limited exposure to previous protease inhibitors. J Clin Virol 2005, 35: 14-9.
27. Walmsley, S., Berstein, B., King, M. et al.; M98-863 Study Team. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 2002, 346: 2039-46.
28. Johnson, M.A., Gathe, J.C. Jr., Podzamczer, D. et al. A once-daily lopinavir/ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimen. J Acquir Immune Defic Syndr 2006, 43: 153-60.
29. Molina, J.M., Wilkin, A., Domingo, P. et al. Once-daily vs. twice-daily lopinavir/ritonavir in antiretroviral-naive patients: 96-week results. 3rd IAS Conference on HIV Pathogenesis and Treatment. Rio de Janeiro 2005, Poster PeWe12.3C12.
30. Murphy, R., da Silva, B., McMillan, F. et al. Seven year follow-up of a lopinavir/ritonavir (LPVZr)-based regimen in antiretroviral (ARV)-naive subjects. 10th European AIDS Conference EACS, Dublin 2005, Poster PE7.9/3.
31. King, M., Lipman, B., Molla, A. et al. Assessing the potential for protease inhibitor cross-resistance in antiretroviral-naive patients experiencing viral rebound on a lopinavir/ritonavir-based regimen. Proc 3rd Eur HIV Drug Resist Workshop, Athens 2005. Abst. 9.9.
32. Conradie, F, Ssanne, I., Venter, W., Eron, J. Failure of lopinavir-ritonavir (Kaletra®)-containing regimen in an antiretroviral-naive patient. AIDS 2004, 18: 1084-5.
33. Hsu, A., I.J., Brun, S., Bernstein, B. et al. Pharmacokinetic- pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2003, 47: 350-9.
34. van der Lee, M., Verweel, G., de Groot, R., Burger, D. Pharmacokinetics of a once-daily regimen of lopinavir/ritonavir in HIV-1-infected children. Antivir Ther 2006, 11: 439-45.
35. Eron, J.J., Feinberg, J., Kessler, H.A. et al. Once-daily versus twice-daily lopinavir/ ritonavir in antiretroviral-naïve HIV-positive patients: A 48-week randomized clinical trial. J Infect Dis 2004, 189: 265-72.
36. van Heeswijk, R.P., Bourbeau, M., Seguin, I., Giguere, P., Garber, G.E., Cameron, D.W. Absence of circadian variation in the pharmacokinetics of lopinavir/ritonavir given as a once daily dosing regimen in HIV-1-infected patients. Br J Clin Pharmacol 2005, 59: 398-404.
37. Awni, W., Chiu, Y.-L., Zhu, T. et al. Significantly reduced food effect and pharmacokinetic variability with a novel lopinavir/ritonavir tablet formulation. 3rd IAS Conference on HIV Pathogenesis and Treatment, Rio de Janeiro 2005, Abst. WeOa0206.
38. Breitenbach, J. Melt extrusion: From process to drug delivery technology. Eur J Pharm Biopharm 2002, 54: 107-17.
39. Breitenbach, J. Melt extrusion can bring new benefits to HIV therapy. Am J Drug Deliv 2006, 4: 61-4.
40. Kaletra® product information (German version). Abbott Laboratories, Queenborough, UK. EU/1/ 01/172/2004, July 2006.
41. Stek, A.M., Mirochnick, M., Capparelli, E. et al.; for the PACTG 1026s Study Team. Reduced lopinavir exposure during pregnancy. AIDS 2006, 20: 1931-9.
42. Department of Health and Human Services. Safety and toxicity of individual antiretroviral agents in pregnancy. July 6, 2006. Available at: http://www.aidsinfo.nih.gov. Accessed September 2006.
43. Department of Health and Human Services. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. July 6, 2006. Available at: http://www.aidsinfo.nih.gov. Accessed September 2006.
44. Bertz, R., Chiu, Y., Naylor, C., Luff, K., Brun, S. Lack of effect of gastric acid reducing agents on lopinavir/ritonavir plasma concentrations in HIV-infected patients. 7th International Conference on Drug Therapy in HIV Infection, Glasgow 2004, Abst. 154.
45. Boffito, M., Arnaud, I., Raiteri, R. et al. Clinical use of lopinavir/ritonavir in a salvage therapy setting: Pharmacokinetics and pharmacodynamics. AIDS 2002, 16: 2081-3.
46. http://medicine.iupui.edu/flockhard/table.htm. Accessed September 25, 2006.
47. Cooper, C.L., van Heeswijk, R., Gallicano, K., Cameron, D.W. A review of low-dose ritonavir in protease inhibitor combination therapy. Clin Infect Dis 2003, 36: 1585-92.
48. Eagling, V.A., Back, D., Barry, M.G. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors ritonavir, saquinavir and indinavir. Br J Clin Pharmacol 1997, 44: 190-4.
49. Hsu, A., Grannemann, G., Bertz, R.J. Ritonavir. Clinical Pharmacokinetics and interactions with other anti-HIV agents. Clin Pharmacokinet 1998, 35: 275-91.
50. Hsu, A., Grannemann, G., Witt, G. et al. Multiple-dose pharmacokinetics of ritonavir in human immunodefficiency virus-infected subjects. Antimicrob Agents and Chemother 1997, 41: 898-905.
51. Grantors, M.T., Wang, J.S., Kajosaari, L.I., Laitila, J., Neuvonen, P.J., Backman, J.T. Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro. Basic Clin Pharmacol Toxicol 2006, 98: 79-85.
52. Kumar, G.N., Dykstra, J., Roberts, E.M. et al. Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: A positive drug-drug interaction. Drug Metab Dispos 1999, 27: 902-8.
53. Crommentuyn, K.M., Kappelhoff, B.S., Mulder, J.W. et al. Population pharmacokinetics of lopinavir in combination with ritonavir in HIV-1-infected patients. Br J Clin Pharmacol 2005, 60: 378-89.
54. Solas, C., Poizot-Martin, I., Drogoul, M.P. et al. Therapeutic drug monitoring of lopinavir/ritonavir given alone or with a non-nucleoside reverse transcriptase inhibitor. Br J Clin Pharmacol 2004, 57: 436-40.
55. Kaletra® product information. Abbott Laboratories Chicago U. 2003, Ref.: 03-5239-R8.
56. Kaletra® package insert. Abbott Laboratories: 2004,03-5341-R10-Rev. February 2004.
57. Lim, M.L., Min, S.S., Eron, J.J. et al. Coadministration of lopinavir/ritonavir and phenytoin results in two-way drug interaction through cytochrome P-450 induction. J Acquir Immune Defic Syndr 2004, 36: 1034-40.
58. Bertz, R., Foit, C., Chiu, Y. et al. Multiple-dose Kaletra® (lopinavir/ritonavir) does not affect the pharmacokinetics of CYP2D6 probe, desipramine. 9th Conference on Retroviruses and Opportunistic Infections, Seattle 2002. Abst. 433.
59. Koks, C.H., Crommentuyn, K., Hoetelmans, R.M. et al. The effect of fluconazole on ritonavir and saquinavir pharmacokinetics in HIV-1-infected individuals. Br J Clin Pharmacol 2001, 51: 631-5.
60. Boffito, M., Bonora, S., Sales, P. et al. Ketoconazole and lopinavir/ritonavir coadministration: Boosting beyond boosting. AIDS Res Hum Retroviruses 2003, 19: 941-2.
61. Vfend® (voriconazole) Swiss product information (German version). Pfizer, A.G., Zurich. Available at: http://www.documed.ch.Accessed November 22, 2006.
62. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. October 10, 2006. Available at: http://www.aidsinfo.nih.gov. Accessed October 12, 2006.
63. Zithromax® (aztihromycin) Swiss product information (German version). Pfizer, A.G., Zurich. Available at: http://www.documed.ch. Accessed November 22, 2005.
64. Erythrocin® (erythromycin) Swiss product information (German version). Abbott, A.G., Baar. Available at: http://www.documed.ch. Accessed Novemver 22, 2006.
65. Bonora, S., Boffito, M., D'Avolio, A. et al. Pharmacokinetics (PKS) of rifabutin (RIF) coadministered with lopinavir/ritonavir (LPV/r) in HIV patients affected by tuberculosis (TB). 2nd IAS Conference on HIV Pathogenenesis and Treatment, Paris 2002, Abst. 863.
66. la Porte, C.J., Colbers, E.B., Bertz, R. et al. Pharmacokinetics of adjusted-dose lopinavirritonavir combined with rifampin in healthy volunteers. Antimicrob Agents Chemother 2004, 48: 1553-60.
67. Kearney, B., Mittan, A., Sayre, J. Pharmacokinetic interaction and long-term safety profile of tenofovir DF and lopinavir/ritonavir. 43rd Interscience Conference on Antimicrobial Agents Chemotherapy, Chicago 2004, Abst. 1617.
68. Ribera, E., Azuaje, C., Lopez, R.M. et al. Atazanavir and lopinavir/ritonavir: Pharmacokinetics, safety and efficacy of a promising double-boosted protease inhibitor regimen. AIDS 2006, 20: 1131-9.
69. Prezista™ prescribing information. Tibotec, Yardley, PA, USA. June 2006, p. 18. Available at: http://www.prezista.com. Accessed June 27, 2006.
70. Staszewski, S., Babacan, E., Stephan, C. et al. The LOPSAQ study: 48-week analysis of a boosted double protease inhibitor regimen containing lopinavir/ritonavir plus saquinavir without additional antiretroviral therapy. J Antimicrob Chemother 2006, 58: 1024-30.
71. Taburet, A.M., Raguin, G., Le Tiec, C. et al. Interactions between amprenavir and the lopinavir-ritonavir combination in heavily pretreated patients infected with human immunodefficiency virus. Clin Pharmacol Ther 2004, 75: 310-23.
72. Khanlou, H., Graham, E., Brill, M., Farthing, C. Drug interaction between amprenavir and lopinavir/ritonavir in salvage therapy. AIDS 2002, 16: 797-8.
73. Bertz, R.J., Foit, C., Ashbrenner, E. et al. Assessment of the steady-state pharmacokinetic interaction of lopinavir/ritonavir with either indinavir or saquinavir in healthy subjects. 42nd Interscience Conference on Antimicrobial Agents Chemotherapy, San Diego 2002, Abst. A-1822.
74. Ribera, E., Lopez, R.M., Diaz, M. et al. Steady-state pharmacokinetics of a double boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in immunodefficiency virus-infected adults. Antimicrob Agents Chemother 2004, 48: 4256-62.
75. Stephan, C., von Hentig, N., Kourbeti, I. et al. Saquinavir drug exposure is not impaired by the boosted double protease inhibitor combination of lopinavir/ritonavir. AIDS 2004, 18: 503-8.
76. Leith, J., Walmsley, S., Katlama, C., Arasteh, K., Pierone, G., Blick, G.; BI1182.51 Study Team. Pharmacokinetics and safety of tipranavir/ritonavir (TPV/r) alone or in combination with saquinavir (SOV), amprenavir (APV), or lopinavir (LPV): Interim analysis of BI1182.51. 5th International Workshop on Clinical Pharmacology of HIV Therapy, Rome 2004, Abst. 5.1.
77. Samaras, K., Pett, S., Gowers, A., McMurchie, M., Cooper, D.A. Iatrogenic Cushing's syndrome with osteoporosis and secondary adrenal failure in human immunodeficiency virus-infected patients receiving inhaled corticosteroids and ritonavir-boosted protease inhibitors: Six cases. J Clin Endocrinol Metab 2005, 90: 4394-8.
78. Shitara, Y, Sugiyama, Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: Drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther 2006, 112: 71-105.
79. Crestoi® product labeling. AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA. Available at: http://www.fda.gov/cder/foi/label/2005/ 21366slr005lbl.pdf. Accessed November 22, 2006.
80. Vogel, M., Voigt, E., Michaelis, H.C. et al. Management of drug-to-drug interactions between cyclosporine A and the protease-inhibitor lopinavir/ritonavir in liver-transplanted HIV-infected patients. Liver Transpl 2004, 10: 939-44.
81. Jain, A.B., Venkatamaranan, R., Eghtesad, B. et al. Effect of coadministered lopinavir and ritonavir (Kaletra®) on tacrolimus blood concentration in liver transplantation patients. Liver Transpl 2003, 9: 954-60.
82. Clarke, S., Mulcahy, F., Bergin, C. et al. Absence of opioid withdrawal symptoms in patients receiving methadone and the protease inhibitor lopinavir-ritonavir. Clin Infect Dis 2002, 34: 1143-5.
83. Kaletra® Swiss product information (German vesion). Abbott, A.G., Baar. Available at: http://www.documed.ch. Accessed November 22, 2006.
84. Levitra® Swiss product information (German version). Bayer, A.G., Zurich. Available at: http://www.documed.ch. Accessed September 2006.
85. Levitra® prescribing information. Bayer Pharmaceuticals Corporation, West Haven, CT, USA. Available at: http://www.fda.gov/cder/foi/ label/2003/021400lbl.pdf. Accessed November 22, 2006.
86. Kashuba, A.D., Tierney, C., Downey, G.F., Acosta, E.P., Vergis, E.N., Klingman, K. Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A 5143 results. AIDS 2005, 19: 145-52.
87. von Hentig, N., Mueller, A., Rottmann, C. et al. Pharmacokinetics and tolerability of a combination of indinavir, lopinavir and ritonavir in multiply pretreated HIV-1 infected adults. Eur J Med Res 2006, 11: 236-44.
88. Corbett, A.H., Lim, M., Kashuba, A.D. Kaletra (lopinavir/ritonavir). Ann Pharmacother 2002, 36: 1193-203.
89. Staszewski, S., Dauer, B., Stephan, C., Kurowski, M., von Hentig, N. A new strategy: Boosted double protease inhibitor regimen lopinavir/r plus saquinavir without reverse transcriptase inhibitor. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego 2002, Abst. H-176.
90. Ruane, P., Mendocina, J., Timerman, A. et al. Kaletra® versus nelfinavir in antiretroviral-naive subjects: 60-week comparison in a phase III, blinded, randomized clinical trial. 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, Buenos Aires 2001, Abst. 6.
91. Da Silva, B., King, M., Cernohous, P., Kelly, C., Tressler, R., Brun, S. Risk for body fat composition changes in antiretroviral naive patients treated with lopinavir/ritonavir (LPV/r) or nelfinavir (NFV). 5th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, Paris 2003, Abst. 99.
92. Benson, C.A., Deeks, S., Brun, S.C. et al. Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients. J Infect Dis 2002, 185: 599-607.
93. Bernstein, B., Meseley, J., King, M. et al. Safety of Kaletra®: Results from phase II and III clinical trials. 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, Buenos Aires 2001, Abst. 525.
94. Vogel, M., Rockstroh, J. Safety of lopinavir/ritonavir for the treatment of HIV infection. Expert Opin Drug Saf 2005, 4: 403-20.
95. Danner, S., Brun, S., Richards, B. et al. Kaletra® (lopinavir/ritonavir) and efavirenz: 72-week safety and efficacy evaluation in multiple Pl-experienced patients. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago 2001, Abst. 351.
96. Hicks, C., Brun, S., King, M. et al.; for the M97-765 Study. Kaletra® (Lopinavir/ ritonavir) therapy in single protease inhibitor experienced patients: 144-week follow-up. 8th European Conference on Clinical Aspects and Treatment of HIV Infection, Athens 2001, Abst. P220.
97. Pollard, R., Thompson, M., Hicks, C. et al. Phase III comparison of lopinavir/ritonavir versus investigator-selected protease inhibitors in single-PI experienced, NNRTI-naive patients. 48-week results of study M98-888. 7th International Conference on Drug Therapy in HIV-lnfection, Glasgow 2004, Poster PL 3.2.
98. Eron, J.J., Yeni, P., Gathe, J.J. et al. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: A randomised non-inferiority trial. Lancet 2006, 368: 476-82.
99. De Luca, A., Cozzi-Lepri, A., Antinori, A. et al. MAICNAUI-M. Lopinavir/ritonavir or efavirenz plus two nucleoside analogues as first-line antiretroviral therapy: A non-randomized comparison. Antivir Ther 2006, 11: 609-18.
100. Panagopoulos, P., Tsiodras, S., Antoniadou, A. et al. Efficacy and safety of an anti-retroviral combination regimen including either efavirenz or lopinavir-ritonavir with a backbone of two nucleoside reverse transcriptase inhibitors. Clin Microbiol Infect 2006, 12: 486-9.
101. Riddler, S.A., Haubrich, R., Di Rienzo, G. et al. A prospective, randomized phase III trial of NRTI-, PI-, and NNRTI-sparing regimens for initial treatment of HIV-1 infections - ACTG-5142. XVI International AIDS Conference, Toronto 2006, Abst. THLB0204.
102. Dragsted, U.B., Gerstoft, J., Youle, M. et al. A randomized trial to evaluate lopinavir/ritonavir versus saquinavir/ritonavir in HIV-1-infected patients: The MaxCmin2 trial. Antivir Ther 2005, 10: 735-43.
103. Elston, R.C., Yates, P., Tisdale, M., Richards, N., White, S., DeJesus, E. GW433908(908)/ritonavir(r): 48-week results in PI-experienced subjects: A retrospective analysis of virological response based on baseline genotype and phenotype. XV International AIDS Conference, Bangkok 2004, Abst. MoOrB1055.
104. Johnson, M., Grinsztejn, B., Rodriguez, C. et al. 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures. AIDS 2006, 20:711-8.
105. Cernohous, P., Bernstein, B., Moseley, J., King, M., Bauer, E., Sun, E. Safety and efficacy of lopinavir/ritonavir in women in a phase III study of antiretroviral-naive subjects. XIV International AIDS Conference, Barcelona 2002, Abst. WePeB5972.
106. Saez-Llorens, X., Violari, A., Deetz, C.O. et al. Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children. Pediatr Infect Dis J 2003, 22: 216-24.
107. Saez-Llorens, X., Renz, C., Deetz, CO. et al. Kaletra® (ABT-378/ritonavir) in HIV-infected children at 60 weeks. 8th Conference on Retroviruses and Opportunistic Infections. Chicago 2001, Abst. 680.
108. Leonard, E.G., McComsey, G. Metabolic complications of antiretroviral therapy in children. Pediatr Infect Dis J 2003, 22: 77-84.
109. 3. 10th European AIDS Conference EACS, Dublin 2005, Poster PE7.3/4.
110. Da Silva, B., King, M., Cernohous, P., Brun, S. Lopinavir/ritonavir (LPV/r): Safety, tolerability and efficacy in hepatitis C- and/or hepatitis B-infected patients. Review of clinical trials. XV International AIDS Conference, Bangkok 2004, Abst. MoPeB3285.
111. Sherman, K.E., Shire, N., Cernohous, P. etal. Liver injury and changes in hepatitis C virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients:Lopinavir-ritonavir versus nelfinavir. Clin Infect Dis 2005, 41: 1186-95.
112. Gathe, J., Podzamczer, D., Johnson, M. et al. Once-daily versus twice daily lopinavir/ritonavir in antiretroviral naive patients: 48-week results. 11th Conference on Retroviruses and Opportunistic Infections, San Francisco 2004, Poster 570.
113. Baril, J.G., Ackad, N., Loutfy, M. et al. QD study: Randomized controlled trial of once-daily tenofovir, 3TC and lopinavir/ritonavir versus remaining on the same regimen in HIV-infected patients virologically suppressed on their first Pl-containing HAART regimen. 15th Annual Canadian Conference on HIV/AIDS Research, Quebec City 2006, Abst. 206.
114. Arribas, J.R., Pulido, F., Delgado, R. et al. Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression: 48-week results of a randomized, controlled, open-label, proof-of-concept pilot clinical trial (OK Study). J Acquir Immune Defic Syndr 2005, 40: 280-7.
115. Staszewski, S., Dauer, B., von Hentig, N. et al. The LopSaq Study: 24-week analysis of the double protease inhibitor salvage regimen containing lopinavir (LPV/r) plus saquinavir (SQV) without any additional antiretroviral therapy. 2nd IAS Conference on HIV Pathogenesis and Treatment, Paris 2003, Abst. 10290.
116. Mauss, S., Stechel, J., Willers, R., Schmutz, G., Berger, F, Richter, W.O. Differential hyperlipidemia associated with antiretroviral therapy. AIDS 2004, 17: 189-94.
117. Richter, W., Berger, F, Mauss, S. Lopinavir/ri-tonavir does not alter very-low-density lipoprotein (VLDL) composition in HIV-infected patients. 7th International Conference on Drug Therapy in HIV Infection, Glasgow 2004, Abst. 231.
118. Negredo, E., Molto, J., Burger, D. et al. Lopinavir/ritonavir plus nevirapine as anucleoside-sparing approach in antiretroviral-experienced patients (NEKA study). J Acquir Immune Defic Syndr 2005, 38: 47-52.
119. Martinez, E., Domingo, P., Galindo, M.J. et al. Risk of metabolic abnormalities in patients infected with HIV receiving antiretroviral therapy that contains lopinavir-ritonavir. Clin Infect Dis 2004, 38: 1017-23.
120. Noor, M.A., Flint, O., Maa, J.F., Parker, R.A. Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: Demonstrable differences in vitro and clinically. AIDS 2006, 20: 1813-21.
121. Montessori, V., Press, N., Harris, M., Akagi, L., Montaner, J.S. Adverse effects of antiretroviral therapy for HIV infection. CMAJ 2004, 170: 229-38.
122. Carr, A., Cooper, D.A. Adverse effects of antiretroviral therapy. Lancet 2000, 356: 1423-30.
123. Fellay, J., Boubaker, K., Ledergerber, B. et al. Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Lancet 2001, 358: 1322-7.
124. Sension, M., Shen, Y, Bush, L. et al. Gastrointestinal tolerability after PI/NNRTI substitution of lopinavir/ritonavir. 43rd Annual ICAAC Meeting, Chicago 2003, Abst. 0377.
125. Hammer, S., Saag, M., Schechter, M. et al. Treatment for adult HIV infection. Available at: http://www.iasusa.org/pub/arv_2006.pdf. Accessed November 22, 2006.
126. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in pediatric HIV infection. November 3, 2005. Available at: http://www.aidsinfo.nih.gov. Accessed September 2006.
127. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. May 4, 2006. Available at: http://www.aid-sinfo.nih.gov 2006. Accessed September 25, 2006.